Expanded health coverage sees an increase in enrollments; Antiabortion activists protest against CVS and Walgreens; $26,500 Alzheimer’s drug limits affordability
Nearly 16 Million People Have Selected Health Coverage in ACA Marketplaces
The Biden-Harris administration announced that nearly 16 million people have signed up for an Affordable Care Act (ACA) marketplace health plan since the start of the 2023 Marketplace Open Enrollment Period in November, according to the CMS. This record-breaking enrollment period saw an increase of 13% over last year and includes over 3 million new people to the marketplaces. This expansion has been a top priority for the Biden-Harris administration with the national uninsured rate reaching an all-time low earlier this year.
Antiabortion Activists Confront CVS and Walgreens
Antiabortion activists organized protests outside of CVS and Walgreens in at least 8 states plus Washington, DC, according to POLITICO. These protests are in response to the FDA’s decision to allow retail pharmacies such as CVS and Walgreens to sell abortion pills in states where its legal. These protests are part of a bigger plan to curb abortion access, by targeting big pharmacy chains, including a call-in campaign and a national boycott of chains.
New Alzheimer Drug Will Cost $26,500 A Year
The new drug, lecanemab (Leqembi), is intended to slow the progression of Alzheimer disease and is the second Alzheimer drug to be approved by the FDA in the last 2 years, according to NBC News. However, this drug comes at a high price of $26,500 a year, which would greatly limit the amount of people who could get the drug. Additionally, CMS coverage is restricted for new Alzheimer treatments to only include patients participating in clinical trials.
Trump Administration’s Message to Supreme Court Puts New Wrinkle in Braidwood Case
February 21st 2025The Trump administration argues that HHS Secretary Robert F. Kennedy Jr can overrule the US Preventive Services Task Force to determine the preventive services covered under the Affordable Care Act.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
February 20th 2025While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Read More
Adapting ACA Access Amid Medicaid Transition and Policy Reversals: Molly Dean
February 19th 2025As enrollment shifts to the Affordable Care Act (ACA) marketplace following the unwinding of Medicaid and the Trump administration begins to implement health policy changes, Molly Dean, MSW, Siftwell's policy advisor, shares insight on how to adapt.
Read More